CD274 and non-small cell lung carcinoma: Though nivolumab was approved for advanced NSCLC patients before pembrolizumab, pembrolizumab is the first anti‐PD‐1 drug approved as first‐line treatment for advance NSCLC patients with PD‐L1 TPS ≥50%.